GLP-1 Remote Delivery and Monitoring: The New Poster Child of Virtual care?

GLP-1 remote delivery and monitoring represent a significant advancement in virtual care, especially in addressing diabetes and obesity. GLP-1 receptor agonists, effective in regulating blood sugar and inducing weight loss, are now conveniently delivered to patients' homes via sophisticated telehealth platforms.

In this meeting, we will explore the future prospects of incorporating GLP-1 therapies into virtual care models and how they can streamline treatment processes, improve patient adherence, and provide real-time data for personalised care.

Join us to discuss:

• What are the current challenges we face in managing obesity effectively, especially in the context of remote care?

• What strategies are in place for monitoring the progress of patients receiving GLP-1 therapy remotely for obesity?

• What are the potential future advancements in GLP-1 therapy delivery and monitoring that could further enhance virtual care?